Arkstone Expands Maternal Care with NeoSafe™: Now Integrating Breastfeeding Safety into OneChoice Reports

BOCA RATON, Fla., Feb. 13, 2025 /PRNewswire/ -- Arkstone, the leader in laboratory infectious disease guidance and antimicrobial stewardship, proudly introduces NeoSafe™, a significant expansion of its OneChoice platform. Building upon OneChoice's existing pregnancy treatment guidance, NeoSafe™ now integrates breastfeeding considerations—providing healthcare providers with the most comprehensive antimicrobial safety recommendations for both pregnant and nursing mothers.

Antimicrobial treatment during pregnancy and breastfeeding presents unique challenges, as certain medications may pose risks to fetal development or be transmitted through breast milk, potentially affecting infant health. OneChoice has long provided AI-enhanced pregnancy treatment guidance, and with NeoSafe™, that capability now extends to breastfeeding—ensuring even greater precision in maternal care.

"With NeoSafe™, we're expanding our commitment to maternal and infant safety," said Dr. Ari Frenkel, Chief Science Officer at Arkstone. "OneChoice has already helped clinicians navigate safe prescribing during pregnancy. Now, with the addition of breastfeeding data, we are delivering an even more complete solution—providing clarity where uncertainty once existed."

With the launch of NeoSafe™, OneChoice reports now provide even more patient-specific treatment guidance by factoring in both pregnancy and breastfeeding safety:

• Expanded Maternal Care Framework – OneChoice already accounted for pregnancy status in its antimicrobial recommendations. NeoSafe™ now enhances this capability by incorporating breastfeeding safety insights, ensuring a complete maternal care solution.
• Seamless Lab & Clinician Input – Labs can include pregnancy and breastfeeding status when submitting patient data, while clinicians using OneChoice Plus can update this information for real-time adjustments.
• Minimized Infant Risk – Helps providers adjust medication selection and breastfeeding schedules to reduce unnecessary infant exposure while maintaining effective maternal treatment.

"NeoSafe™ enhances OneChoice's capabilities through Arkstone's Antimicrobial Intelligence framework, ensuring clinicians receive the most precise, evidence-based recommendations available," added Dave Gross, Chief Technology Officer at Arkstone. "By integrating breastfeeding safety, we are giving providers the confidence to prescribe with precision, protecting both mother and child."

NeoSafe™ reflects Arkstone's commitment to advancing antimicrobial stewardship through precision-guided medicine. By expanding OneChoice's maternal care capabilities, Arkstone ensures that every prescription considers both pregnancy and breastfeeding safety—helping healthcare providers make the most informed decisions to protect both mother and baby.

About Arkstone

Arkstone is a global leader in infectious disease clinical guidance and antimicrobial stewardship. Through its AI-enhanced (Antimicrobial Intelligence) solutions, Arkstone provides evidence-based, patient-specific recommendations to combat antibiotic misuse and antimicrobial resistance, ensuring smarter, safer prescribing decisions worldwide.

For more information, visit www.arkstone.ai or contact [email protected].

Media Contact
Sol Levi
1-833-933-ARK-3
[email protected]

SOURCE Arkstone